



Media Contact
Dan McFadden
dmcfadden@oculusis.com
(425) 836-3103

JIM SCHUTZ JOINS OCULUS INNOVATIVE SCIENCES AS GENERAL COUNSEL AND CORPORATE SECRETARY

PETALUMA, CA (September 9, 2003)— Hoji Alimi, president and founder of Oculus Innovative Sciences (www.oculusis.com), today announced that Jim Schutz has joined the company as general counsel and corporate secretary. With more than 15 years of legal experience, Mr. Schutz will be responsible for all legal issues in the Americas, Europe and Asia.

Mr. Schutz previously served as general counsel and secretary to Jomed Incorporated, previously known as EndoSonics, a mid-sized (+/- 600 employee) multi-site medical device company, whose products included intravascular ultrasound, interventional cardiology catheters and cardiac assist devices. Prior to Jomed, Mr. Schutz was in-house with Urban Media, a Silicon Valley-based startup targeting fiber-optic broadband to business. Mr. Schutz earned a B.A. from the University of California, San Diego, and his J.D. from the University of San Francisco.

“We are thrilled to have Jim join the Oculus team. He is a valuable addition combining extensive legal expertise and practical business experience,” said Alimi. “We expect Jim will make an immediate and valuable contribution to our company, and I am confident that he will help us continue our vigorous growth in the medical device and pharmaceutical marketplace.”

About Oculus

Oculus Innovative Sciences, headquartered in Petaluma, California, is pioneering innovative services and technologies that can improve patient health worldwide. The company has at its foundation two wholly owned subsidiaries, MicroMed Consulting Services and AquaMed Technologies. Oculus has overseen the evolution of the Microcyn 60 disinfectant from technology to product as well as the development of an anti-cancer drug (L3) that shows promise in the prevention of many aggressive cancers including cervical cancer and melanomas. This same L3 compound has great potential in other applications based on its cell growth inhibition characteristics such as the drug-eluting stent products reducing restenosis. For more information, please visit us at www.oculusis.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. These forward-looking statements relate to, among other things, plans and timing for the introduction of our products, statements about future market conditions, supply and demand conditions, revenues, gross margins, operating expenses, profits and other expectations, intentions and plans contained in this press release that are not historical fact. Our expectations as expressed in this press release depend upon our ability to develop, manufacture and supply products that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in the health sciences market. In light of the many risks and uncertainties surrounding this market, you should understand that we cannot assure you that the forward-looking statements contained in this press release will be realized.